<PAGE>

                                                                    EXHIBIT 4.10

                                  FORM 53-901F

                                 SECURITIES ACT

                          MATERIAL CHANGE REPORT UNDER
             SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
               AND EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

ITEM 1.  REPORTING ISSUER

         Cardiome Pharma Corp.
         6190 Agronomy Road, 6th Floor
         Vancouver, BC V6T 1Z3

ITEM 2.  DATE OF MATERIAL CHANGE

         March 1, 2005

ITEM 3.  PRESS RELEASE

         March 1, 2005 - Vancouver, British Columbia

ITEM 4.  SUMMARY OF MATERIAL CHANGE

         Cardiome Pharma Corp announced that it has filed a short form
         preliminary base PREP prospectus with the Canadian securities
         regulators and a registration statement with the U.S. Securities and
         Exchange Commission in connection with an offering of 8,500,000 common
         shares.

ITEM 5.  FULL DESCRIPTION OF MATERIAL CHANGE

         See attached press release.

ITEM 6.  RELIANCE ON SECTION 85(2) OF THE SECURITIES ACT (BRITISH COLUMBIA) AND
         EQUIVALENT LEGISLATION OF OTHER JURISDICTIONS

         Not Applicable.

ITEM 7.  OMITTED INFORMATION

         Not Applicable.

ITEM 8.  SENIOR OFFICER

         Name:         Christina Yip
         Title:        Vice President, Finance and Administration
         Phone No.:    604-677-6905

ITEM 9.  STATEMENT OF SENIOR OFFICER

         The foregoing accurately discloses the material change referred to
         herein.

<PAGE>

Dated at Vancouver, British Columbia, this 1st day of March, 2005.

                                CARDIOME PHARMA CORP.





                                PER:    /s/ Christina Yip
                                      -----------------------------
                                      CHRISTINA YIP,
                                      VICE PRESIDENT, FINANCE AND ADMINISTRATION

IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE
FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE
LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.


<PAGE>


[CARDIOME LOGO]           6190 Agronomy Rd             Tel: 604-677-6905
                             6th Floor                 Fax: 604-677-6915
                            Vancouver, BC              Website: www.cardiome.com
                           V6T 1Z3 CANADA
--------------------------------------------------------------------------------

                  FOR IMMEDIATE RELEASE NASDAQ: CRME TSX: COM

            CARDIOME PHARMA CORP. FILES PRELIMINARY PROSPECTUS WITH
            CANADIAN AND U.S. SECURITIES AUTHORITIES FOR AN OFFERING
                           OF 8,500,000 COMMON SHARES

VANCOUVER, CANADA, MARCH 1, 2005 Cardiome Pharma Corp. (NASDAQ: CRME, TSX: COM)
announced today that it has filed a short form preliminary base PREP prospectus
with the Canadian securities regulators and a registration statement with the
U.S. Securities and Exchange Commission in connection with an offering of
8,500,000 common shares. In connection with this offering, Cardiome plans to
grant to the underwriters a 30-day option to purchase up to an additional
1,275,000 common shares to cover over-allotments, if any. All of the shares will
be offered by the company and will consist of newly issued common shares. The
offering is expected to be made primarily in the United States.

UBS Investment Bank and CIBC World Markets Corp. will be acting as joint book
running managers in this offering. The syndicate of underwriters also includes
GMP Securities Ltd., Leerink Swann & Company, First Associates Investments Inc.
and Orion Securities Inc. When available, copies of the preliminary prospectus
may be obtained from UBS Investment Bank, Prospectus Department, 299 Park
Avenue, New York, NY 10171 or 161 Bay Street, Suite 4100, Toronto, Ontario, M5J
2S1 and from CIBC World Markets Corp. by email at useprospectus@us.cibc.com, by
fax at 212-667-6136 or 161 Bay Street, 6th Floor, Toronto, Ontario, M5J 2S8.

A registration statement relating to these securities has been filed with the
U.S. Securities and Exchange Commission, but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of the securities in any state in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state.

ABOUT CARDIOME PHARMA CORP.

Cardiome is a life sciences company focused on developing proprietary drugs to
treat or prevent cardiovascular diseases. Its current efforts are focused on the
treatment of atrial arrhythmias and congestive heart failure.

FOR FURTHER INFORMATION:
Don Graham
Director of Corporate Communication
(604) 676-6963 or Toll Free: 1-800-330-9928
Email: dgraham@cardiome.com

The statements in this press release relating to the proposed public offering
include certain forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained herein are based on the company's current
expectations but they involve a number of risks and uncertainties. The timing of
events could differ materially from those anticipated in the forward-looking
statements as a result of risks and uncertainties, which include, without
limitation, capital markets conditions and other risks detailed in our filings
with the Securities and Exchange Commission available at http://www.sec.gov. You
are urged to consider these factors carefully in evaluating the forward-looking
statements herein and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety by this
cautionary statement. The forward-looking statements made herein speak only as
of the date of this press release and the company undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent events or
circumstances, except as required by law. The Toronto Stock Exchange has not
reviewed and does not accept responsibility for the adequacy or accuracy of this
release.